Advertisement
Screener

BIOGEN INC. (BIIB) Increase (Decrease) in Income Taxes Payable

2.8 / 5 stars · 68/120 Roast Me

BIOGEN INC. Increase (Decrease) in Income Taxes Payable

BIOGEN INC. (BIIB) reported Increase (Decrease) in Income Taxes Payable of $18.40 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-04-29

  • BIOGEN INC. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was $18.40M, a 73.37% decline year-over-year.
  • BIOGEN INC. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was -$194.00M, a 1282.93% decline year-over-year.
  • BIOGEN INC. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was -$229.40M, a 428.65% decline year-over-year.
  • BIOGEN INC. increase (decrease) in income taxes payable for the quarter ending 2025-06-30 was -$603.80M.
  • BIOGEN INC. increase (decrease) in income taxes payable for fiscal 2025 was -$958.10M, a 1320.51% decline from fiscal 2024.
  • BIOGEN INC. increase (decrease) in income taxes payable for fiscal 2024 was $78.50M.
  • BIOGEN INC. increase (decrease) in income taxes payable for fiscal 2023 was -$299.00M.
  • BIOGEN INC. increase (decrease) in income taxes payable for fiscal 2022 was -$142.30M, a 161.66% decline from fiscal 2021.
Period endIncrease (Decrease) in Income Taxes Payable 3 monthIncrease (Decrease) in Income Taxes Payable 3 month as first filedIncrease (Decrease) in Income Taxes Payable 6 monthIncrease (Decrease) in Income Taxes Payable 6 month as first filedIncrease (Decrease) in Income Taxes Payable 9 monthIncrease (Decrease) in Income Taxes Payable 12 monthIncrease (Decrease) in Income Taxes Payable 12 month as first filed
2026-03-31$18.40M
10-Q · filed 2026-04-29
-$175.60M
derived: sum of 2 quarters · filed 2026-04-29
-$405.00M
derived: sum of 3 quarters · filed 2026-04-29
-$1.01B
derived: sum of 4 quarters · filed 2026-04-29
2025-12-31-$194.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06
-$423.40M
derived: sum of 2 quarters · filed 2026-02-06
-$1.03B
derived: sum of 3 quarters · filed 2026-02-06
-$958.10M
10-K · filed 2026-02-06
2025-09-30-$229.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
-$833.20M
derived: sum of 2 quarters · filed 2025-10-30
-$764.10M
10-Q · filed 2025-10-30
-$747.70M
derived: sum of 4 quarters · filed 2026-04-29
2025-06-30-$603.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
-$534.70M
10-Q · filed 2025-07-31
-$518.30M
derived: sum of 3 quarters · filed 2026-04-29
-$448.50M
derived: sum of 4 quarters · filed 2026-04-29
2025-03-31$69.10M
10-Q · filed 2026-04-29
$85.50M
derived: sum of 2 quarters · filed 2026-04-29
$155.30M
derived: sum of 3 quarters · filed 2026-04-29
$149.80M
derived: sum of 4 quarters · filed 2026-04-29
2024-12-31$16.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06
$86.20M
derived: sum of 2 quarters · filed 2026-02-06
$80.70M
derived: sum of 3 quarters · filed 2026-02-06
$78.50M
10-K · filed 2026-02-06
2024-09-30$69.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
$64.30M
derived: sum of 2 quarters · filed 2025-10-30
$62.10M
10-Q · filed 2025-10-30
-$122.10M
derived: sum of 4 quarters · filed 2026-02-06
2024-06-30-$5.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
-$7.70M
10-Q · filed 2025-07-31
-$191.90M
derived: sum of 3 quarters · filed 2026-02-06
-$224.30M
derived: sum of 4 quarters · filed 2026-02-06
2024-03-31-$2.20M
10-Q · filed 2025-05-01
-$186.40M
derived: sum of 2 quarters · filed 2026-02-06
-$218.80M
derived: sum of 3 quarters · filed 2026-02-06
-$366.20M
derived: sum of 4 quarters · filed 2026-02-06
2023-12-31-$184.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06
-$216.60M
derived: sum of 2 quarters · filed 2026-02-06
-$364.00M
derived: sum of 3 quarters · filed 2026-02-06
-$299.00M
10-K · filed 2026-02-06
2023-09-30-$32.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
-$179.80M
derived: sum of 2 quarters · filed 2024-10-30
-$114.80M
10-Q · filed 2024-10-30
-$156.90M
derived: sum of 4 quarters · filed 2025-02-12
2023-06-30-$147.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
-$82.40M
10-Q · filed 2024-08-01
-$124.50M
derived: sum of 3 quarters · filed 2025-02-12
-$158.80M
derived: sum of 4 quarters · filed 2025-02-12
2023-03-31$65.00M
10-Q · filed 2024-04-24
$22.90M
derived: sum of 2 quarters · filed 2025-02-12
-$11.40M
derived: sum of 3 quarters · filed 2025-02-12
-$179.20M
derived: sum of 4 quarters · filed 2025-02-12
2022-12-31-$42.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12
-$76.40M
derived: sum of 2 quarters · filed 2025-02-12
-$244.20M
derived: sum of 3 quarters · filed 2025-02-12
-$142.30M
10-K · filed 2025-02-12
2022-09-30-$34.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$202.10M
derived: sum of 2 quarters · filed 2023-11-08
-$100.20M
10-Q · filed 2023-11-08
-$129.90M
derived: sum of 4 quarters · filed 2024-02-14
2022-06-30-$167.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25
-$65.90M
10-Q · filed 2023-07-25
-$95.60M
derived: sum of 3 quarters · filed 2024-02-14
-$6.60M
derived: sum of 4 quarters · filed 2024-02-14
2022-03-31$101.90M
10-Q · filed 2023-04-25
$72.20M
derived: sum of 2 quarters · filed 2024-02-14
$161.20M
derived: sum of 3 quarters · filed 2024-02-14
$267.90M
derived: sum of 4 quarters · filed 2024-02-14
2021-12-31-$29.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14
$59.30M
derived: sum of 2 quarters · filed 2024-02-14
$166.00M
derived: sum of 3 quarters · filed 2024-02-14
$230.80M
10-K · filed 2024-02-14
2021-09-30$89.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25
$195.70M
derived: sum of 2 quarters · filed 2022-10-25
$260.50M
10-Q · filed 2022-10-25
$177.70M
derived: sum of 4 quarters · filed 2023-02-15
2021-06-30$106.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20
$171.50M
10-Q · filed 2022-07-20
$88.70M
derived: sum of 3 quarters · filed 2023-02-15
-$400.60M
derived: sum of 4 quarters · filed 2023-02-15
2021-03-31$64.80M
10-Q · filed 2022-05-03
-$18.00M
derived: sum of 2 quarters · filed 2023-02-15
-$507.30M
derived: sum of 3 quarters · filed 2023-02-15
-$225.70M
derived: sum of 4 quarters · filed 2023-02-15
2020-12-31-$82.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15
-$572.10M
derived: sum of 2 quarters · filed 2023-02-15
-$290.50M
derived: sum of 3 quarters · filed 2023-02-15
-$67.50M
10-K · filed 2023-02-15
2020-09-30-$489.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20
-$207.70M
derived: sum of 2 quarters · filed 2021-10-20
$15.30M
10-Q · filed 2021-10-20
-$33.20M
derived: sum of 4 quarters · filed 2022-02-03
2020-06-30$281.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22
$504.60M
10-Q · filed 2021-07-22
$456.10M
derived: sum of 3 quarters · filed 2022-02-03
$213.80M
derived: sum of 4 quarters · filed 2022-02-03
2020-03-31$223.00M
10-Q · filed 2021-04-22
$174.50M
derived: sum of 2 quarters · filed 2022-02-03
-$67.80M
derived: sum of 3 quarters · filed 2022-02-03
$68.80M
derived: sum of 4 quarters · filed 2022-02-03
2019-12-31-$48.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03
-$290.80M
derived: sum of 2 quarters · filed 2022-02-03
-$154.20M
derived: sum of 3 quarters · filed 2022-02-03
$16.10M
10-K · filed 2022-02-03
2019-09-30-$242.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21
-$105.70M
derived: sum of 2 quarters · filed 2020-10-21
$64.60M
10-Q · filed 2020-10-21
$70.70M
derived: sum of 4 quarters · filed 2021-02-03
2019-06-30$136.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22
$306.90M
10-Q · filed 2020-07-22
$313.00M
derived: sum of 3 quarters · filed 2021-02-03
$445.20M
derived: sum of 4 quarters · filed 2021-02-03
2019-03-31$170.30M
10-Q · filed 2020-04-23
$176.40M
derived: sum of 2 quarters · filed 2021-02-03
$308.60M
derived: sum of 3 quarters · filed 2021-02-03
$234.40M
derived: sum of 4 quarters · filed 2021-02-03
2018-12-31$6.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03
$138.30M
derived: sum of 2 quarters · filed 2021-02-03
$64.10M
derived: sum of 3 quarters · filed 2021-02-03
$321.70M
10-K · filed 2021-02-03
2018-09-30$132.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22
$58.00M
derived: sum of 2 quarters · filed 2019-10-22
$315.60M
10-Q · filed 2019-10-22
$1.45B
derived: sum of 4 quarters · filed 2020-02-06
2018-06-30-$74.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24
$183.40M
10-Q · filed 2019-07-24
$1.32B
derived: sum of 3 quarters · filed 2020-02-06
$1.60B
derived: sum of 4 quarters · filed 2020-02-06
2018-03-31$257.60M
10-Q · filed 2019-04-24
$1.39B
derived: sum of 2 quarters · filed 2020-02-06
$1.68B
derived: sum of 3 quarters · filed 2020-02-06
$1.76B
derived: sum of 4 quarters · filed 2020-02-06
2017-12-31$1.13B
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06
$1.42B
derived: sum of 2 quarters · filed 2020-02-06
$1.50B
derived: sum of 3 quarters · filed 2020-02-06
$1.30B
10-K · filed 2020-02-06
2017-09-30$285.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23
$365.60M
derived: sum of 2 quarters · filed 2018-10-23
$170.50M
10-Q · filed 2018-10-23
$85.30M
derived: sum of 4 quarters · filed 2019-02-06
2017-06-30$80.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-24
-$114.70M
10-Q · filed 2018-07-24
-$199.90M
derived: sum of 3 quarters · filed 2019-02-06
-$270.60M
derived: sum of 4 quarters · filed 2019-02-06
2017-03-31-$195.10M
10-Q · filed 2018-04-24
-$280.30M
derived: sum of 2 quarters · filed 2019-02-06
-$351.00M
derived: sum of 3 quarters · filed 2019-02-06
-$704.50M
derived: sum of 4 quarters · filed 2019-02-06
2016-12-31-$85.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06
-$155.90M
derived: sum of 2 quarters · filed 2019-02-06
-$509.40M
derived: sum of 3 quarters · filed 2019-02-06
-$232.60M
10-K · filed 2019-02-06
2016-09-30-$70.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24
-$424.20M
derived: sum of 2 quarters · filed 2017-10-24
-$147.40M
10-Q · filed 2017-10-24
-$575.60M
derived: sum of 4 quarters · filed 2018-02-01
2016-06-30-$353.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25
-$76.70M
10-Q · filed 2017-07-25
-$151.70M
10-Q · filed 2016-07-21
-$504.90M
derived: sum of 3 quarters · filed 2018-02-01
-$608.10M
derived: sum of 4 quarters · filed 2018-02-01
2016-03-31$276.80M
10-Q · filed 2017-04-25
$225.10M
10-Q · filed 2016-04-21
-$151.40M
derived: sum of 2 quarters · filed 2018-02-01
-$254.60M
derived: sum of 3 quarters · filed 2018-02-01
-$306.60M
derived: sum of 4 quarters · filed 2018-02-01
2015-12-31-$428.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01
-$531.40M
derived: sum of 2 quarters · filed 2018-02-01
-$583.40M
derived: sum of 3 quarters · filed 2018-02-01
-$429.40M
10-K · filed 2018-02-01
-$410.20M
10-K · filed 2016-02-03
2015-09-30-$103.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26
-$155.20M
derived: sum of 2 quarters · filed 2016-10-26
-$1.20M
10-Q · filed 2016-10-26
2015-06-30-$52.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21
$102.00M
10-Q · filed 2016-07-21
$102.02M
10-Q · filed 2015-07-24
2015-03-31$154.00M
10-Q · filed 2016-04-21
$154.02M
10-Q · filed 2015-04-24
2014-12-31$40.30M
10-K · filed 2017-02-02
$61.00M
10-K · filed 2016-02-03
2014-06-30$49.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24
$31.11M
10-Q · filed 2015-07-24
2014-03-31-$18.64M
10-Q · filed 2015-04-24
2013-12-31$156.80M
10-K · filed 2016-02-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29